PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy’s Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy’s exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics’ leading products – Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.

The engagement with Dr Reddy’s utilised PharmaVentures’ significant and established pharmaceutical transactions experience in the healthcare transactions sector. Dr Fintan Walton, Chief Executive, PharmaVentures said, “We are delighted to bring another successful outcome to one of our important international clients, Dr Reddy’s. We are proud to have acted as advisor and broker to one of India’s premier pharmaceutical companies, particularly in assisting them to achieve their business goals in the increasingly expanding Russian/CIS market”.

PharmaVentures acted as advisor and broker to the Dow Chemical Corporation in the sale of its small molecule pharmaceutical manufacturing business to Dr Reddy’s, under a separate agreement in 2008.

Over the past 18 years, PharmaVentures has acted as advisors to numerous pharmaceutical and biopharmaceutical clients in transactions covering the licensing, merger, acquisition, divestment and joint venture activities for companies located worldwide.